Q&A with Dr Alexandre Akoulitchev Chief Scientific Officer at Oxford Biodynamics PLC (LON:OBD)

Oxford Biodynamics PLC (LON:OBD) Chief Scientific Officer Dr Alexandre Akoulitchev caught up with DirectorsTalk for an exclusive interview to discuss their latest ALS biomarker data

 

Q1: The latest results presented at Boston CNS World Summit are based on extensive biomarker analysis, multi-centre studies and large patient cohorts, some of them observed repeatedly over a period of 3 and 6 months. Can you tell us more on how Oxford Biodynamics’ work aligns itself with the ALS field, key clinical specialists and institutions?

A1: The results that were presented in Boston is actually a follow-up of very extensive work with several key leaders in the field and very successful results built on a very successful collaboration. We’ve been engaged from the very beginning with Massachusetts General Hospital and Chief of Neurology, Professor Merit Cudkowicz and with the very generous support from Innovate UK, we extended our work in the UK with the University of Oxford, the Nuffield Department of Clinical Neurosciences, Professor Kevin Talbot. In fact, ended up working the three centres in the States, the UK and also in Malaysia where we have a separate subsidiary with the University Hospital Malaya, Professor Goh Khean Jin. All uniquely substantial cohorts of patients, both Caucasian and Asian, and a lot of credit should go to help in guidance, collaboration and clinical expertise.

 

Q2: Now, the FDA has approved only two drugs for ALS, Riluzole from Sanofi and Radicava from Mitsubishi Tanabe, how would your biomarker work help in more successes in therapeutic developments for ALS?

A2: ALS proves to be a very difficult disease with a lot of failures in clinical development and what we do answers very particular questions relevant from drug development, in particular not only the early pre-symptomatic detection of the disease but also the prognostic stratification so that one can populate a trial, include the right patients early with fast-progressing ALS.

There is multiple evidence that we might be dealing with subtypes within the disease. Our readouts on biomarker platforms are picking systemic and genetic differences. It might be a very valuable addition to all joint efforts today to try to understand the subtypes and match potential treatments, treatments in development with the right sub group of patients.

 

Q3: The biomarker approach that Oxford Biodynamics has developed and the examples of your applications, how useful is it to other actionable patient stratifications in neurogenerative and neuropsychiatric conditions?

A3: It is very relevant, and we are very glad that, first of all, we’re were able to build up and present evidence within ALS taking some of the signatures for validation already but also the field itself has been paying very close attention to genome architecture, chromosome conformation signatures, all the modalities we’re working with.

Within the peer group space, there is significant evidence that our platform, our operation, would be very applicable to such diseases as Alzheimer’s, Multiple Sclerosis, many other neurogenerative conditions, autism, post-traumatic stress disorder, depression.

The very nature of what we do and what we measure brings out readouts based on blood so we’re dealing with liquid biopsy, non-invasive results, which from a clinical practice point of view, it’s particularly valuable today.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques)

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations(DNA protein complexes) that regulate normal and disease biology

    Oxford BioDynamics

    Holos Life Sciences using EpiSwitch

    Epigenetics represents the impact of the combination of genetic, lifestyle and environmental factors on humans. We utilise EpiSwitch™, a proprietary biomarker discovery platform licensed from our AIM listed shareholder Oxford Biodynamics Plc. Based on the latest advances in gene

    Oxford BioDynamics

    Episwitch Methodology

    Oxford BioDynamics’ EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs provide a robust, stable framework of

    Oxford BioDynamics

    5 Ways to Help Kids Cope with a Parent’s ALS

    One of my biggest concerns is how my husband’s ALS will affect our children. They were both under 5 when Todd was diagnosed and while they are growing up, their father continues to lose strength. A

    Oxford BioDynamics

    EpiSwitch Technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework from which changes in the regulation of

    Oxford BioDynamics

    Rare Disease Day 2020

    An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought

    Oxford BioDynamics

    Oxford BioDynamics’ EpiSwitchFeatured in Presentations

    Data yielded by application of OBD’s 3D genome architecture technology platform, EpiSwitch™ was presented at The Society for Immunotherapy of Cancer’s 34th Annual Meeting. The poster presentations indicate that the biomarkers identified by EpiSwitch, using blood samples

    Oxford BioDynamics

    Dementia rates in Europe to double by 2050

    Today, at a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg), Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates

    Oxford BioDynamics

    EpiSwitch technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework from which changes in the regulation of a

    Oxford BioDynamics

    What is ALS?

    ALS, also known as Motor Neuron Disease (MND), Lou Gehrig’s Disease, and Charcot’s disease, is a progressive neurodegenerative disease which attacks motor neurons in the brain and spinal cord resulting in the wasting away of muscle

    Oxford BioDynamics

    Oxford Biodynamics publish Annual Report

    Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announced that copies of its annual report

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    What is ALS?

    Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disease that destroys nerve cells in the brain  and the spinal cord and causes disability. It is also known as Lou Gehrig’s disease. The term “A-myo-trophic” is derived from the